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A b s t r a c t  
Complexation of nicergoline with β-cyclodextrin (β-CD) into an inclusion complex has been used 
successfully to improve the drugÊs solubility, dissolution rate and hence per oral absorption. In 
addition, masking of the bitter taste was also achieved. The preparation of inclusion complexes was 
performed using two different techniques, namely; physical mixing and kneading. The apparent 
stability constant (Kc) of the complex was calculated from the phase solubility analysis. Compatibility 
of nicergoline and β-CD complex with disintegrants and superdisintegrants were evaluated using 
powder x-ray diffractometry (PXRD), differential scanning calorimetry (DSC), and fourier transform 
infrared spectroscopy (FTIR). The morphology of complex particles was studied using scanning 
electron microscopy. Pharmaceutical characterization confirmed that all additives were compatible 
with the drug and no signs of physical or chemical interaction were detected. Orodispersible tablets 
(ODTs) of nicergoline complexed with β-CD and containing 7-9 % camphor had rapid disintegration 
time (7-12 seconds) and fast drug release profiles (90-100 % in 10 minutes). Therefore, nicergoline 
ODTs are considered a valuable choice dosage form with improved per oral absorption and taste 
acceptability. 
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Introduction 
Orodispersible tablets have become extremely popular per oral 
dosage forms in recent years [1]. Food and Drug Administration 
(FDA) defines orally disintegrating tablets as solid dosage forms 
containing a active pharmaceutical ingredient and disintegrate 
rapidly within few seconds when placed on the tongue [2]. ODTs 
offer the convenience of ease of swallowing in a liquefied form, 
provide good stability and accurate dosing [3]. They also possess 
simple manufacturing methodologies, small packaging size and 
favourable handling by patients [4]. Rapid disintegrating tablets 
result in quick dissolution and rapid absorption which provide rapid 
onset of action and increased bioavailability of drugs that are 
absorbed from mouth, pharynx and oesophagus [5]. The bitter 
after-taste of many drugs makes it difficult to be formulated as 
ODTs. The taste-masked tablet should give appropriate mouth feel 
using flavours and sweeteners included into ODTs formulations [6]. 
Numerous techniques have been used for producing highly-porous 
structure in the tablet matrix to facilitate and shorten disintegration 
time. These may include sublimation methods, inclusion of one or 
more disintegrant and/or superdisintegrants and also using fast 
dissolving sugar excipients such as mannitol and lactose. 
Conventional tablets contain highly water soluble ingredients; 
however, they often fail to disintegrate rapidly because of low 
porosity. To improve the porosity, volatile substances such as 
camphor can be used in tableting process, which are then 
sublimated from the formed tablet. Undesirable taste is one of 
several important formulation problems that are encountered with 
certain drugs taken by per oral route and the problem of bitter taste 
is always a challenge to the formulator pharmacist [7]. Nicergoline 
is a semi-synthetic ergoline derivative indicated for treatment of 
AlzheimerÊs disease and other types of dementia [8]. It has a 
molecular weight of 484.4 gm and melting point from 136oC to 138 
oC, soluble in ethanol, chloroform and slightly soluble in ether [9]. 
The chemical name of nicergoline is: [(8β)-10-methoxy-1,6-
dimethylergoline-8-methanol-5-bromo-3-pyridine carboxylate.] [10]. 
Nicergoline is extensively metabolised mainly by hydrolysis and N-
demethylation and excreted in the urine as free and conjugated 
(glucuronide) metabolites [9]. Nicergoline has poor water solubility 
(0.002 mg/ml), therefore its absorption is expected to be dependent 
on dissolution rate [11].  This study aims at resolving problems of 
nicergoline regarding its poor water solubility, decreased 
bioavailability and its remarkable bitter after taste using drug 
complexed with β-cyclodextrin (β-CD). β-cyclodextrin provides 
essential and first choice properties for poorly soluble drugs by 
virtue of its hydrophilic surface and hydrophobic core [7] and [12]. It 
has a molecular weight of 1134.98 gm and extensively used for 
improvement of dissolution of many drugs such as gliclazide [13], 
corticosteroids [14], warfarin [15], Ibuprofen [16] and colchicine 
[17]. In this study, β -CD was used together with superdisintegrants 
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and a subliming agent to formulate and evaluate improved 
orodispersible tablet formulations of nicergoline with high 
bioavailability and patient acceptability.  
Material and Methods  
Materials 
Nicergoline was a gift from Delta Pharma, Cairo Egypt. Granular 
mannitol, Pharmaburst and Sodium stearyl fumarate (SSF) were 
purchased from (SPI Pharma, USA). Ac-di-sol (sodium 
crosscarmellose) was purchased from E. Merk-Germany. Explotab 
(sodium starch glycolate) was obtained from FMC, CoLtd., 
Pennsylvania U.S.A. Saccharin sodium and crosspovidone 
(crosslinked sodium carboxymethyl cellulose) were kindly supplied 
by Chemical Industries Development Company (CID), Giza, Egypt. 
Camphor was obtained as a free sample from El-Nasr 
pharmaceutical chemical company, Cairo, Egypt. 
Preparation and evaluation of nicergoline physical 
mixtures  
Accurately weighed amounts of nicergoline (200 mg) and each of 
the used excipients namely granular mannitol, Ac-Di-Sol, Explotab 
(SSG), Crosspovidone, sodium stearyl fumarate (SSF), saccharin 
sodium, and camphor in ratios of 1:1 were mixed in a mortar. 
Samples from the freshly prepared mixtures were stored in glass 
vials and kept in hot air oven at 60 ĈC for four weeks. Samples of 
the drug-excipient mixtures were removed at appropriate time 
intervals for examination of physical changes in appearance and/or 
colour, caking or signs of liquefaction. Other physico-
pharmaceutical characterizations were performed using DSC, 
FTIR, SEM and Phase solubility analyses. 
Preparation of nicergoline- β-cyclodextrin inclusion 
complex 
The inclusion complex of nicergoline and β-cyclodextrin were 
prepared at stoichiometric molar ratio of 1:1 using two approaches; 
a) physical mixing after appropriate sieving of accurately weighed 
amounts of nicergoline (100 mg) and β-cyclodextrin (234.31 mg) 
using a mortar and pestle. b) Kneading method, in which the 
inclusion complex of nicergoline and β-cyclodextrin was prepared 
by kneading B-CD into a paste using a small amount of water. A 
solution of the drug in a small volume of methanol (3 ml) was 
added and the mixture was ground in the mortar till evaporation of 
the organic solvent. The theoretical drug content in the complex 
should be 29.91 % (w/w) based on 1:1 molar ratio. However, the 
actual content of entrapped nicergoline was determined practically 
by dissolving 100 mg of complex in 100 ml phosphate buffer (pH 
6.8) followed by measuring the UV-absorbance at 280 nm. The 
drug content in the binary system of β-cyclodextrin/drug was 
calculated and found to be 20.38 %. This means that more than 68 
% of theoretical drug content was entrapped into the complex. 
Phase Solubility analysis of Nicergoline -
Betacyclodextrin 
The phase solubility technique permits the evaluation of the affinity 
between β-CD and nicergoline in water. Phase solubility studies 
were performed according to the method reported by Higuchi and 
Connors [18]. Nicergoline samples in amounts that exceeded its 
maximum solubility were taken into 10 mls volumetric flasks then 
10 mls of distilled water containing various concentrations of β-CD 
(2, 4, 6, 8 and 10 mmol.) were added. The flasks were sealed and 
continuously shaken using a magnetic stirrer for 48 hours at 25 ÀC. 
Aliquots from the suspension were withdrawn using, filtered 
immediately through a whattman filter paper and approximately 
diluted with distilled water. Samples were then analyzed using UV 
spectrophotometer (Jasco-V-530, Japan) at 280 nm. Blank solution 
was prepared from β-CD in water and measured in the same way.  
 
 
Figure.1: Phase solubility diagram of nicergoline-β-cyclodextrin 
inclusion complex 
 
The apparent stability constant (Kc) according to the hypothesis of 
(1:1) stochiometric ratio of complex was calculated after plotting of 
phase solubility diagram (see Fig.1) and  applying equation-1  
 
 KC 1:1 = slope / So(1-slope) .......................Eq. 1 
 
Where So is the equilibrium solubility of nicergoline in water 
determined experimentally. The aqueous solubility of nicergoline 
increased linearly as a function of β-cyclodextrin concentration 
(see Fig.1). The slope of the regression line was less than 1 
suggesting formation of a 1:1 complex [18]. The calculated 
apparent stability constant (Kc) obtained from the slope of the 
linear phase solubility diagram and experimentl So  value was 
found to be 125 mol-1 [20-22]. 
 
Scanning Electron Microscopy 
The surface morphology of the binary mixtures was examined and 
compared to both of β-cyclodextrin and nicergoline particles. Few 
spikes of powders were precisely fixed to aluminium stubs using 
double sided adhesive carbon discs and then were made 
electrically conductive by coating with gold sputter under vacuum 
(SPI-Module Sputter Coater, SPI Supplies Inc., USA). Samples 
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In-vitro dissolution rate studies 
The dissolution behaviour of nicergoline/β-CD tablet formulations 
was performed using USP XXIV Basket apparatus (Hanson 
Research, SR 8 plus model, U.S.A). Samples of six tablets 
corresponding to each formulation were placed individually into 
stainless steel baskets and immersed into the dissolution medium 
(900 ml phosphate buffer pH 6.8) operated at a temperature of 37o 
μ 0.5oC. The rate of agitation was kept at 50 r.p.m. Five milliliter 
samples were withdrawn at specific time intervals, filtered and the 
absorbance was measured spectrophotometrically at 280 using 
U.V spectrophotometer (UV-VIS spectrophotometer; Jasco, V-530, 
Japan). 
 
Evaluation of taste masking character of drug/ β-CD 
complex 
Taste masking ability of prepared formulations was evaluated using 
taste panel of six healthy human volunteers. The test was carried 
out according to University approved protocol indicating the ethics 
of dealing with volunteers. They were asked to sign a voluntary 
consent indicating their agreement and awareness about sharing in 
this experiment [25]. In this test, volunteers were given a little 
sample of pure drug (2 mg) or equivalent sample from β-CD 
complex formulations to taste and evaluate the bitterness and give 
their response after ten seconds. The response was evaluated on 
a scale from 0-4, where 0 = good, 1= tasteless, 2= slightly bitter, 3= 
bitter and 4 = very bitter. Each volunteer was asked to detect the 
taste of both drug and the complex to act as his or her own control. 
The results of this test indicated a score of 2 for the complex 
between nicergoline and β -CD on the scale which means a slightly 
bitter taste. Further improvement can be done by the use of a 
sweetener [26].  
 
Pharmaceutical characterization of Nicergoline 
Orodispersible tablets 
The prepared tablets were evaluated for various official and 
nonofficial specifications including weight variation, hardness and 
friability. Twenty tablets were weighed accurately and their average 
weight was calculated. Tablet thickness and diameter of 10 tablets 
were evaluated using Vernier caliper (Shanghai, China). The 
average value of diameter and thickness was then calculated (see 
Table 2). Tablet hardness was determined for ten tablets from each 
formulation using a tablet hardness tester (Dr-Schleuniger, 
Pharmaton, USA). The percentage friability was evaluated using a 
tablet friabilator (Pharma Test, Germany). The apparatus was 
rotated at 25 r.p.m for a period of 4 minutes and then the solid 
contents re-weighed. The percentage loss in weights was 
calculated and taken as a measure of friability (see Table 2). Drug 
content was evaluated for the prepared tablets after grinding of ten 
tablets and dissolving in 500 ml phosphate buffer (pH 6.8) followed 
by spectrophotometric analysis at 280 nm. The disintegration time 
was determined using disintegration test apparatus (Erweka, USA). 
A tablet was placed in each of the six tubes of the apparatus and 
one disc was added to each tube. The test medium was composed 
of 500 ml pH 6.8 phosphate buffer [27]. The time (in seconds) 
taken for complete disintegration of tablets with no large masses 
remained in the apparatus was measured. 
 
                                                         Table 2: Pharmaceutical characteristics of prepared Orodispersible tablets: 
Formula No. Mean Weight mg μ S.D. 
Mean Diameter 
(mm) μ S.D. 
Mean Thickness 
(mm) μ S.D. 
Hardness (kg) μ 
S.D % Friability μ S.D 
Disintegration       
time (sec) μ S.D 
F1 119.33 μ  2.08 8.10 μ 0.02 2.06 μ 0.01 2.90 μ 0. 60 0.28 μ 0.02 9.74 μ 0.43
F2 121.33 μ 1.15 8.08 μ 0.01 2.05 μ 0.01 2.80 μ 1.46 0.58 μ .001 9.27 μ 0.07
F3 118.33 μ 2.08 8.08 μ 0.01 2.05 μ 0.02 2.20 μ 0.54 0.30 μ 0.04 7.48 μ 0.24
F4 121.53 μ 1.56 8.11 μ 0.01 2.05 μ 0.02 3.10 μ 1.36 0.28 μ 0.03 12.98 μ 0.28
F5 118.57 μ 2.40 8.14 μ 0.01 2.10 μ 0.01 3.60 μ 0.77 0.29 μ 0.02 11.09 μ 0.35
F6 119.57 μ  2.69 8.08 μ 0.01 2.08 μ 0.01 3.60 μ 0.95 0.29 μ 0.02 10.81 μ 0.66
F7 119.57 μ 2.30 8.13 μ 0.01 2.06 μ 0.01 3.30 μ 1.45 0.56 μ 0.05 9.76 μ 1.37
F8 116.83 μ 0.99 8.08 μ 0.01 2.12 μ 0.01 3.20 μ 0.76 0.86 μ 0.04 9.64 μ 0.22
F9 115.43 μ 1.33 8.09 μ 0.00 2.10 μ 0.01 3.30 μ 1.27 0.29 μ 0.03 9.63 μ 0.89
F10 120.37 μ 0.85 8.16 μ 0.01 2.14 μ 0.01 3.80 μ 1.45 0.42 μ 0.05 10.94 μ 2.27
F11 119.00 μ 1.73 8.07 μ 0.01 2.06 μ 0.01 3.60 μ 0.76 0.43 μ 0.04 9.54 μ 0.47
F12 121.63 μ 1.21 8.13 μ 0.01 2.10 μ 0.02 3.10 μ 1.27 0.43 μ 0.02 9.54 μ 0.47
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Effect of storage at high temperature on tablet 
disintegration and drug release 
This test aimed at studying the effect of ageing at high temperature 
on the disintegration and release of nicergoline from the selected 
formulation after 6 and 12 weeks. The release data of nicergoline 
from fresh and stored formulation (F3) at 40 μ 0.5 oC for 6 and 12 
weeks are given in Fig. 11. The results showed insignificant 
difference (p <0.05) in the disintegration or release pattern of 
nicergoline from the stored formulation compared to freshly 
prepared analogues.  
Results and Discussion  
Physical characterization 
  
Drug-excipients physical mixtures fresh and those stored at 60oC 
for 4 weeks showed no change in physical appearance. All the 
prepared nicergoline ODTs showed acceptable weight variation 
range from 115.43 to 121.63 mg with standard deviation less than 
2%. The prepared tablets showed uniformity of thickness and 
diameter (2.053 to 2.143 mm) and (8.076 to 8.17 mm) respectively. 
It was also observed that all the prepared tablets showed a 
percentage of fines which did not exceed the permissible limit of 
friability (1.4%). All nicergoline tablets showed hardness values 
ranging from 2- 4 kilograms. After tablet compression and 
subjecting to sublimation, the constant weight indicated complete 
removal of subliming agent [28]. Increasing camphor concentration 
from 3-9 % led to decreased disintegration time (<7.5 seconds) 
and formulations (F1 ă F3) had the most rapid disintegration due to 
the porous structure formed [29]. However, formulations F4 ă F12 
containing superdisintegrants as well as camphor showed higher 
disintegration time values. This can be attributed to swellability and 
viscous matrices formed by the superdisintegrants leading to delay 
of the disintegration time (see Table 1 &2). Therefore sublimation 
can be considered as an effective method of preparing high 
porosity tablets that can undergo rapid disintegration in saliva [24]. 
 
Scanning Electron Microscopy 
 
The SEM of nicergoline, nicergolineăβ-cyclodextrin systems are 
shown in Fig.2. Nicergoline appeared as irregular shaped particles, 
whilst β-cyclodextrin showed a parallelogram shape. In nicergoline 
ă β-cyclodextrin physical mixture small particle (nicergoline) 
adhered on the surface of β-cyclodextrin. However, the kneaded 
product appeared as relatively bulky agglomerated particles and 
the original morphology of raw materials disappeared and it was 
not possible to differentiate between its 2 components. This 
prominent change in particlesÊ shape was indicative of the 
presence of new solid phase. 
 
Differential Scanning Calorimetry 
 
The DSC thermogram of nicergoline showed one main prominent 
characteristic endothermic melting peak at 137 oC (see Fig. 3). The 
DSC thermograms of the drug with other excipients are shown in 
Fig. 3-4. The therrmogram of β-cyclodextrin showed that it has one 
endothermic peak at 88.93oC, while its physical mixture with 
nicergoline in molar ratio (1:1) showed three endothermic peaks at 
80.52, 98.49 and 133.86oC representing the sum of the individual 
curves of nicergoline and β-cyclodertrin with slight reduction in 
peak height of drug. This reduction can be attributed to dilution 
(reduced purity of both due to co-mixing) indicating no interaction. 
However, the inclusion complex prepared by kneading method 
showed three endothermic peaks at 72.24, 95.91 and 120.39 oC 
with disappearance of the characteristic peak of the drug which 
suggested the insertion of the drug molecule inside the β-CD cavity 
forming a true inclusion complex [30]. As there was no 
appearance, shift or disappearance of peaks and absence of 
variations in the corresponding enthalpy of the characteristic 
peaks, incompatibility of the ingredients can be excluded [31]. 
However, some broadening of peaks leading to changes in the 
area, onset and little changes in peak temperature may occur due 
to just mixing of components (dilution) without indicating any 
significant interaction [32]. Based on the previous DSC results, all 
the used additives were found to be compatible with the drug. The 
compatibility of nicergoline with the used excipients was further 
confirmed using IR spectroscopy. 
 
 
Figure.3: DSC thermograms for nicergoline, disintegrants and their 
physical mixtures 
Elbary et al. International Journal of Drug Delivery 5 (1) 110-120 [2013] 
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Figure.4: DSC thermograms for nicergoline, superdisintegrants and 
their physical mixtures 
 
Fourier Transform Infrared (IR) Spectroscopy 
IR spectrum of nicergoline (Fig. 5) exhibited the characteristic 
bands corresponding to the functional groups of the drug at 
3423.99 cm-1 characteristic for (- N ă H stretch) from (3500 ă 
3300), at 1720.19 cm-1 from (1760 ă 1665 cm-1) characteristic for 
(C = 0 stretch), at 1081.87 cm-1 characteristic for (C ă O) and at 
1463.71 and 1427.07 cm-1 for (C = C) stretching of aromatic rings. 
The β-cyclodextrin IR spectrum exhibited a broad strong band at 
3396.99 cm-1 (3500 ă 3200) cm-1 of (O ă H stretch) and at 1030 
cm-1 of (C ă O). IR spectra of nicergoline with β-cyclodextrin in both 
physical mixture and kneaded complex (Fig.6) showed the same 
characteristic bands of the drug in the same regions and the same 
ranges. IR spectra of nicergoline with all the excipients (see Fig. 5-
6) under test in mixtures showed the same characteristic bands of 
the drug in the same regions and ranges, indicating no sign of 
chemical interaction between the drug and excipients. 
 
 
 
Figure.5: IR spectra of Nicergoline; disintegrants, fresh physical 
and stored mixtures at 60 ĈC 
 
Powder X-ray Diffractometry 
 
The presence of several different peaks in nicergoline diffraction 
pattern (Fig. 7) indicated that the drug is in crystalline form. The 
diffraction patterns of physical mixture showed simply the sum of 
each component, indicating the presence of nicergoline in 
crystalline state. In contrast, diminution of the diffraction peaks in 
the kneaded complex suggested that it is less crystalline than the 
physical mixture indicating that nicergoline and β-cyclodxtrin 
formed an inclusion complex. 
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